Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study

被引:8
作者
Xue, Qiuji [1 ]
Xiong, Xianjun [2 ]
Feng, Yi [1 ]
Yao, Lan [1 ]
Chen, Shanquan [1 ]
Xiang, Li [1 ]
机构
[1] Huazhong Univ Sci & Technol, Sch Med & Hlth Management, Tongji Med Coll, Wuhan 430030, Peoples R China
[2] China Hlth Insurance Res Assoc, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
antipsychotics; China; prescription pattern; schizophrenia; socioeconomic factors; MEDICATION ADHERENCE; HEALTH-SERVICES; CHOICE; DRUGS;
D O I
10.1097/YIC.0000000000000024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Medication is critical in schizophrenia therapy, and prescription patterns have changed considerably over the past 20 years in China. This study attempts to evaluate the prescription patterns of antipsychotics for inpatients with schizophrenia in China and to identify factors influencing these patterns. Claims data of inpatients diagnosed with schizophrenia in 2010 were derived from the reimbursement database of Wuhan and Wuxi. A total of 5251 inpatients received antipsychotic medications, of whom 29.0% received second-generation antipsychotics apart from clozapine (SGAs#), 13.7% received clozapine (CLO), 13.5% received first-generation antipsychotics (FGAs), 43.8% received at least both drug classes, and 5.1% used FGAs, CLO as well as SGAs#. Multinomial logistic regression for 2904 identified inpatients showed that factors of drug reimbursement policy, duration of hospitalization, age group, and municipality were statistically significant in antipsychotic medication. Drug list B and the 25-45 age group presented a significant relationship with SGAs# prescription (FGAs vs. SGAs#). Furthermore, the 12-30-day duration of hospitalization and the 25-45 age group showed a significant relationship with SGAs# prescription (CLO vs. SGAs#). Socioeconomic factors such as health insurance policies, especially reimbursement policy of drugs and payment system, as well as mental health resource distribution are important in antipsychotic prescription in China. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:288 / 295
页数:8
相关论文
共 33 条
[1]   Development and status of health insurance systems in China [J].
Barber, Sarah L. ;
Yao, Lan .
INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT, 2011, 26 (04) :339-356
[2]   INCENTIVES AND PROVIDER PAYMENT METHODS [J].
BARNUM, H ;
KUTZIN, J ;
SAXENIAN, H .
INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT, 1995, 10 (01) :23-45
[3]   The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements [J].
Buchanan, Robert W. ;
Kreyenbuhl, Julie ;
Kelly, Deanna L. ;
Noel, Jason M. ;
Boggs, Douglas L. ;
Fischer, Bernard A. ;
Himelhoch, Seth ;
Fang, Beverly ;
Peterson, Eunice ;
Aquino, Patrick R. ;
Keller, William .
SCHIZOPHRENIA BULLETIN, 2010, 36 (01) :71-93
[4]   Launch of the health-care reform plan in China [J].
Chen, Zhu .
LANCET, 2009, 373 (9672) :1322-1324
[5]   Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change [J].
Chong, MY ;
Tan, CH ;
Fujii, S ;
Yang, SY ;
Ungvari, GS ;
Si, TM ;
Chung, EK ;
Sim, K ;
Tsang, HY ;
Shinfuku, N .
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2004, 58 (01) :61-67
[6]  
Desjarlais R., 1996, World Mental Health: Problems and Priorities in Low-Income Countries
[7]   Antipsychotic medication adherence: Is there a difference between typical and atypical agents? [J].
Dolder, CR ;
Lacro, JP ;
Dunn, LB ;
Jeste, DV .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (01) :103-108
[8]   Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia [J].
Edlinger, Monika ;
Hofer, Alex ;
Rettenbacher, Maria A. ;
Baumgartner, Susanne ;
Widschwendter, Christian G. ;
Kemmler, G. ;
Neco, Nazanin Ahmadian ;
Fleischhacker, W. Wolfgang .
SCHIZOPHRENIA RESEARCH, 2009, 113 (2-3) :246-251
[9]   Tracking China's health reform [J].
Guo, Yan ;
Shibuya, Kenji ;
Cheng, Gang ;
Rao, Keqin ;
Lee, Liming ;
Tang, Shenglan .
LANCET, 2010, 375 (9720) :1056-1058
[10]   Medical decision making in antipsychotic drug choice for schizophrenia [J].
Hamann, J ;
Langer, B ;
Leucht, S ;
Busch, R ;
Kissling, W .
AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (07) :1301-1304